Beam Therapeutics Inc. Common Stock (BEAM) Stock
Key stats
- Market cap
- $2.54B
- Price / Earnings ratio
- -30.0x
- EPS (TTM)
- -$3.57
- Volume
- Loading
- 52-week high
- $38.26
- 52-week low
- $20.23
Source: third-party data provider, as of October 24, 2026
Compare with BEAM
Recent news

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
BEAM

Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
BEAM

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
BEAM

BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
BEAM
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 47.46
- MACD 12/26/9
- -0.35
- EMA 9 of MACD
- -0.46
- MACD histogram
- 0.11
- SMA 50
- $26.07
- Price below SMA 50
- EMA 50
- $25.79
- Price below EMA 50
- SMA 200
- $28.29
- Price below SMA 200
- EMA 200
- $27.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?
BEAM

Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
Cathie Wood-Led Ark Invest Sells AMD, SPCX, GOOG Stocks — But Loads Up On CMPS, NTLA, CRSP And Other Healthcare Firms
BEAM

CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
CRSP, NTLA, BEAM, PRME, EDIT Shares Slip — Did Claude Just Spook Gene-Editing Stocks?
BEAM

BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS Law
BEAM

3 Promising Genomics Stocks in the Spotlight in 2026
3 Promising Genomics Stocks in the Spotlight in 2026
BEAM

4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
4 Gene-Editing Biotech Stocks Worth Watching for Long-Term Gains
BEAM

BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in Focus
BEAM

Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue Estimates
BEAM

Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
Cathie Wood Is Buying This Up-and-Coming Biotech Stock. Should You Follow Her Lead?
BEAM

Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
Gene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battle
BEAM
News tone: automated (AI) classification of the article's content, not a price prediction.
About Beam Therapeutics Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. John M. Evans M.B.A. | CEO & Director | 1978 |
| Mr. Sravan Kumar Emany | Chief Financial Officer | 1978 |
| Dr. Giuseppe Ciaramella Ph.D. | President | 1969 |
| Dr. Christine P. Bellon J.D., Ph.D. | Chief Legal Officer & Corporate Secretary | 1966 |
| Dr. Amy Simon M.D. | Chief Medical Officer | 1965 |
| Dr. Feng Zhang Ph.D. | Co-Founder | — |
| Dr. David R. Liu Ph.D. | Co-Founder | — |
| Dr. J. Keith Joung M.D., Ph.D. | Co-Founder | — |
| Ms. Bethany J. Cavanagh M.B.A. | Senior VP of Finance, Treasurer & Principal Accounting Officer | — |
| Dr. Manmohan Singh Ph.D. | Chief Technology Officer | — |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of October 24, 2026
Technical indicators
- RSI 14
- 47.46
- MACD 12/26/9
- -0.35
- EMA 9 of MACD
- -0.46
- MACD histogram
- 0.11
- SMA 50
- $26.07
- Price below SMA 50
- EMA 50
- $25.79
- Price below EMA 50
- SMA 200
- $28.29
- Price below SMA 200
- EMA 200
- $27.20
- Price below EMA 200
Calculated by Gotrade from daily closing prices, as of October 22, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $65.00
- Average
- $72.50
- High
- $80.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -7.6 | -16.2 | +9.6 | |||||||||
| 2022 | -15.8 | +13.3 | -22.0 | -37.4 | -13.7 | +13.8 | +58.3 | -7.2 | -14.3 | -8.0 | +4.1 | -14.7 |
| 2023 | +16.4 | -12.5 | -20.5 | +1.9 | +3.8 | -1.8 | -3.3 | -18.7 | +2.5 | -1.7 | +33.5 | -7.9 |
| 2024 | -11.0 | +49.4 | -17.1 | -35.0 | +9.6 | -3.9 | +37.3 | -12.0 | +0.4 | -6.4 | +19.4 | -12.4 |
| 2025 | +4.9 | +2.9 | -22.2 | +13.0 | -20.2 | +5.1 | +12.4 | -13.1 | +48.8 | +3.6 | +4.5 | +15.3 |
| 2026 | +1.8 | +1.9 | -16.9 | +25.2 | +7.3 | +10.2 | -23.8 | +13.6 | -15.7 | +0.7 |



